Details of Disease

General Information of Disease (ID: DISESK0U)

• Disease Name: Heart failure with preserved ejection fraction
• Disease Class: BD11: Left ventricular failure
• Disease Hierarchy:
  DIS01GPL: Grass pollen hypersensitivity
  DISESK0U: Heart failure with preserved ejection fraction
• ICD Code: ICD-11: ICD-11: BD11.0

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 7 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Mitiperstat	DM0BL2G	Phase 2/3	Small molecule	[1]
HU6	DMQ4523	Phase 2	Small molecule	[2]
XXB750	DMA3W2D	Phase 2	NA	[3]
JK07	DMXDIN8	Phase 1	Fusion protein	[4]
PF-07328948	DMKL7PL	Phase 1	NA	[5]
SZ002	DMD28EX	Clinical trial	NA	[6]
SZ003	DM15YZC	Clinical trial	NA	[6]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] ClinicalTrials.gov (NCT04986202) A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for Up to 48 Weeks in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%. U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT05284617) Exploratory Phase 2A, Double-blind, Placebo-Controlled, Dose Escalation Study to Determine the Safety, Tolerability, PD, and PK of HU6 for the Treatment of Subjects With Obese Heart Failure With Preserved Ejection Fraction (HFpEF). U.S.National Institutes of Health.
• [3] ClinicalTrials.gov (NCT05328752) A Randomized, Participant- and Investigator-blinded, Sponsor Open-label, Placebo-controlled, Single and Multiple Dose Study to Investigate the Safety and Tolerability of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF). U.S.National Institutes of Health.
• [4] ClinicalTrials.gov (NCT05322616) A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Assess the Safety and Tolerability of JK07 in Subjects With Heart Failure With Preserved Ejection Fraction (HFpEF). U.S.National Institutes of Health.
• [5] ClinicalTrials.gov (NCT05654181) A PHASE 1, RANDOMIZED, DOUBLE-BLIND, SPONSOR-OPEN, PLACEBO-CONTROLLED, 4-PERIOD, CROSSOVER, FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ASCENDING ORAL DOSES OF PF-07328948 ADMINISTERED TO HEALTHY ADULT PARTICIPANTS. U.S.National Institutes of Health.
• [6] Clinical pipeline report, company report or official report of Sarfez Pharmaceuticals